Cargando…
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease
Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week randomized, double-blind,...
Autores principales: | Kim, Gi-Ae, Cho, Hyun Chin, Jeong, Soung Won, Kang, Bo-Kyeong, Kim, Mimi, Jung, Seungwon, Hwang, Jungwook, Yoon, Eileen L., Jun, Dae Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142612/ https://www.ncbi.nlm.nih.gov/pubmed/37111380 http://dx.doi.org/10.3390/ph16040623 |
Ejemplares similares
-
ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model
por: Lee, Eun Jeoung, et al.
Publicado: (2022) -
Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis
por: Park, Byung Young, et al.
Publicado: (2015) -
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
por: Oh, Ju Hee, et al.
Publicado: (2022) -
Discordance diagnosis between B-mode ultrasonography and MRI proton density fat fraction for fatty liver
por: Lee, Chul-min, et al.
Publicado: (2023) -
Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
por: Ahn, Sang Bong, et al.
Publicado: (2019)